998
Participants
Start Date
July 24, 2024
Primary Completion Date
December 31, 2024
Study Completion Date
July 31, 2025
Y-3 for injection
Qualified subjects were randomly divided into groups in a 1:1 ratio and received continuous treatment with Y-3 injection (40 mg/dose, qd) or placebo control drug. The treatment was performed 10 times for 10 days.
Placebo control group
Qualified subjects were randomly divided into groups in a 1:1 ratio and received continuous treatment with Y-3 injection (40 mg/dose, qd) or placebo control drug. The treatment was performed 10 times for 10 days.
RECRUITING
Beijing Tiantan Hospital Capital Medical University Beijing, Beijing
Collaborators (1)
Neurodawn Pharmaceutical Co., Ltd.
INDUSTRY
Beijing Tiantan Hospital
OTHER